8-K: Glucotrack Secures $2M Via Dilutive Convertible Notes

Glucotrack, Inc. has issued $2.56 million in senior secured convertible promissory notes for $2 million cash, reflecting a 22% original issue discount, alongside warrants for additional shares.

Summary

• Glucotrack, Inc. has entered into a securities purchase agreement to issue senior secured convertible promissory notes totaling $2,564,102.65 in principal amount for an aggregate cash purchase price of $2,000,000.
• This transaction reflects a 22% original issue discount.
• The notes bear interest at 8% per annum and mature in nine months.
• Upon an Event of Default, the interest rate increases to 18% per annum.
• The notes are secured by a lien on substantially all of the company's assets.
• The notes are convertible into common stock at a price of 80% of the lowest daily VWAP over 15 trading days, subject to a floor price, or a fixed price of $0.6390, whichever is lower.
• Warrants to purchase 8,025,360 shares of common stock were also issued, exercisable at $1.5975 per share for five years.
• The company also announced a 1-for-2 reverse stock split effective October 26, 2026, to help regain compliance with Nasdaq's minimum bid price requirement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the dilutive nature of the financing, the significant original issue discount, and the company's ongoing struggles to maintain Nasdaq listing compliance, which indicates financial distress.

Positives

• Secured $2 million in cash financing to support operations.
• The notes are convertible, potentially allowing for future equity conversion rather than cash repayment.
• The company is taking steps, including a reverse stock split, to address Nasdaq listing requirements.

Negatives

• The financing involves a significant 22% original issue discount, indicating a high cost of capital.
• The conversion price is set at a discount to market price (80% of VWAP), which is dilutive to existing shareholders.
• The company issued warrants representing a substantial number of shares (200% of the principal amount divided by the conversion price), further increasing potential dilution.
• The company is actively seeking to regain compliance with Nasdaq's minimum bid price requirement, suggesting prior non-compliance and financial pressure.
• The notes are senior secured obligations, meaning they have priority over other unsecured debt and equity holders in case of liquidation.

Risks

• The company's ability to maintain compliance with Nasdaq listing rules, particularly the minimum bid price requirement, remains a significant risk.
• The dilutive nature of the convertible notes and warrants could significantly impact the value of existing shares.
• The company's financial condition may necessitate further dilutive financings or capital raises.
• Failure to obtain stockholder approval for the issuance of shares exceeding the Exchange Cap (19.99%) could lead to penalties or cash repayment obligations.
• The company is subject to various covenants and potential Events of Default that could trigger accelerated repayment or other remedies for the noteholders.

Future Outlook

The company is undertaking a reverse stock split to improve its stock price and Nasdaq listing compliance. The convertible notes and warrants introduce potential future dilution, and the company's ability to manage its financial obligations and listing requirements will be critical.

Management Comments

• The Reverse Stock Split is intended to help Glucotrack regain compliance with the $1.00 minimum bid price requirement for continued listing of its Common Stock on Nasdaq.
• The Reverse Stock Split is also intended to make the prevailing price of its Common Stock more attractive to a broader group of institutional investors.
• Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Industry Context

StockSavvy.ai notes that this type of financing, involving convertible debt with original issue discounts and warrants, is common for companies facing financial challenges or seeking to fund operations when traditional equity markets are less accessible. The focus on regaining Nasdaq compliance highlights the pressures many smaller-cap companies face in meeting exchange listing standards.

Comparison to Industry Standards

• The 22% original issue discount is on the higher end for convertible note financings, suggesting a higher perceived risk by investors.
• Issuing warrants at 200% of the principal amount is a common practice to sweeten convertible debt deals, but it significantly increases potential future dilution compared to deals with lower warrant coverage.
• The conversion price being set at 80% of the VWAP with a floor price is a typical structure for such instruments, aiming to provide downside protection for the investor while allowing for conversion at a discount to the prevailing market price.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the conversion of notes and exercise of warrants, and a reverse stock split which may not be viewed favorably by all investors.
• Creditors: The notes are senior secured obligations, giving noteholders priority over other unsecured creditors in the event of default or liquidation.
• Employees: Continued operations depend on successful financing and compliance, impacting job security.
• Nasdaq: The company is under scrutiny to maintain listing compliance, with potential delisting if requirements are not met.

Next Steps

• The company must file a registration statement within ten (10) days after the Closing (October 22, 2026) to cover the resale of registrable securities.
• The company must use commercially reasonable efforts to have the registration statement declared effective within forty-five (45) days of the Closing.
• The company must file a proxy statement within thirty (30) days of the Closing to obtain stockholder approval for issuances exceeding the Exchange Cap.
• The company must use its best efforts to obtain stockholder approval within ninety (90) days of the Closing.
• The company must maintain a closing bid price of at least $1.00 until November 9, 2026, to comply with the Nasdaq exception.
• The company must apply 50% of ELOC proceeds to repayment of amounts owing under the notes until paid in full.

Key Dates

Recommendation

The financing is highly dilutive, carries a significant original issue discount, and is undertaken by a company struggling with Nasdaq listing compliance. These factors suggest considerable financial distress and a high risk of further value erosion for existing shareholders.

Keywords

Convertible Promissory Note, Senior Secured Debt, Warrants, Private Placement, Financing, Dilution, Nasdaq Compliance, Reverse Stock Split